Biotech Co., Ltd. announced that the inactivated vaccine for bovine nodular dermatosis developed by Jinyu Baoling Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the company, was approved by the Ministry of Agriculture and Rural Affairs as a Class 1 new veterinary drug and obtained a “New Veterinary Drug Registration Certificate”. This product is used to prevent bovine nodular skin disease and is a veterinary drug needed for emergency treatment of major animal epidemics in China. Currently, this product has not obtained an approval number for veterinary drug products, and is not yet eligible for marketing and sales. Relevant application work will be carried out in the future. This approval will enrich the company's ruminant sector product matrix and consolidate its competitive position in the veterinary vaccine segment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.